Armonica Technologies secures new patents advancing their long-read DNA successes
Nov 14, 2018, 14:29 ET
ALBUQUERQUE, N.M., Nov. 14, 2018 /PRNewswire/ -- Armonica Technologies, Inc, an Albuquerque, NM-based company focused on building its proprietary long-read DNA sequencing technology (the "Company"), chalked up new Intellectual Property success in 2018 by securing two new patents covering its innovative approach.
As it advances the stage of its technology, the Company is generating excitement within the scientific community. "I believe that Armonica has the potential to transform the genome sciences through ultra-high throughput DNA sequencing," said Dr. Jeremy Edwards, Professor at the University of New Mexico Comprehensive Cancer Center and Scientific Advisor to the Company. "Previous nanopore technology has suffered from serious limitations, namely the ability to control the speed of DNA translocation through a nanopore. In recent years this problem has been partially mitigated using proteins positioned on the nanopore. Armonica has developed an optimal solution to this problem using innovative nanofabrication technology. I am very excited by the technology that Armonica is developing," continued Edwards.
Two new patents covering the Company's proprietary designs were issued by the U.S. Patent and Trademark Office in 2018. In March of 2018, U.S. Patent 9,927,397, titled "Innovative Nanopore Sequencing Technology Including a Self-Assembled Porous Membrane," was issued. More recently, in August 2018, U.S. Patent 10,060,904, titled "Fabrication of Enclosed Nanochannels Using Silica Particles," was issued. These new patents expand the IP portfolio exclusively licensed by the Company.
More importantly, Armonica is demonstrating the promise of its technology through measurable results. Key milestones are being successfully accomplished; additional announcements of these successes are expected by early next year. Armonica's approach emphasizes no library preparation, fast, accurate reads, and a process that preserves the methylation associated with DNA. Scott Goldman, CEO of Armonica, remarked: "The potential and importance of long-read DNA approaches to the future of sequencing are highlighted by industry announcements that occurred earlier this month. It's been exciting to be part of a team that is developing industry leading breakthroughs in the long-read space, and I look forward to announcing some of these key milestone accomplishments in the near future."
About Armonica Technologies, Inc
Armonica Technologies, Inc is an Albuquerque, NM-based company focused on building its proprietary long-read DNA sequencing technology. The Company's mission is to become the gold standard of DNA sequencing for precision medicine research applications. Learn more at www.armonicatech.com
SOURCE Armonica Technologies, Inc